Metraipolis › archive › dc_563e489da083

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy — Europe PMC PMID:41649583

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41649583
DOI
10.1007/s00228-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-06T01:43:38.358Z
SHA-256 of the archived text
bc0aa04504c63a07e1c334748b5e55c9b32090620027e22fa2bfd6a687faf101
Stable URL of this page
https://metraipolis.com/documento/dc_563e489da083

How to cite

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy — Europe PMC PMID:41649583 — Europe PMC (en), https://europepmc.org/article/MED/41649583 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_563e489da083 (Metraipolis archive dc_563e489da083, sha256 bc0aa04504c63a07e1c334748b5e55c9b32090620027e22fa2bfd6a687faf101)
BibTeX
@misc{dc563e489da083,
  title = {CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy — Europe PMC PMID:41649583},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41649583},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_563e489da083; sha256 bc0aa04504c63a07e1c334748b5e55c9b32090620027e22fa2bfd6a687faf101},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41649583. Agents can read the archived copy with the MCP tool read_document.